News

January 29, 2021January 29, 2021

Dosing Begins in Phase 1 Trial of CERC-007

News

Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll ... Read more

January 27, 2021January 27, 2021

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

News

Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. ... Read more

January 25, 2021January 25, 2021

$10M Gift to Open Myeloma Research Center at Ohio State

News

A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation ... Read more

January 22, 2021January 22, 2021

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

News

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 ... Read more

January 20, 2021January 20, 2021

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

News

Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data from ... Read more

January 18, 2021January 18, 2021

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies ... Read more

January 15, 2021January 15, 2021

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

News

The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex (daratumumab) in people with heavily treated ... Read more

January 13, 2021January 13, 2021

PT-112 Shows Promise for Heavily Treated Myeloma Patients

News

Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory multiple myeloma. The findings were shared in ... Read more

January 11, 2021January 11, 2021

MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

News

The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials for the treatment of multiple myeloma. The ... Read more

January 8, 2021January 8, 2021

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

News

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) multiple ... Read more